ahlam1399
07-13-2016, 05:06 AM
FDA panel backs Amgen copy of AbbVie arthritis drug Humira
(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Ynd3wXlfdv0:TaLrNQaZSgk:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Ynd3wXlfdv0:TaLrNQaZSgk:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Ynd3wXlfdv0:TaLrNQaZSgk:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Ynd3wXlfdv0:TaLrNQaZSgk:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Ynd3wXlfdv0:TaLrNQaZSgk:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Ynd3wXlfdv0
(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Ynd3wXlfdv0:TaLrNQaZSgk:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Ynd3wXlfdv0:TaLrNQaZSgk:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Ynd3wXlfdv0:TaLrNQaZSgk:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Ynd3wXlfdv0:TaLrNQaZSgk:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Ynd3wXlfdv0:TaLrNQaZSgk:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Ynd3wXlfdv0